The fourth edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) meeting was held in Venice, Italy, between March 31 and April 1, 2011. The ATST meeting was initially organized as a venue for learning the latest information related to the use of allogeneic transplantation for treating in solid tumors. As new immunological and targeted therapy approaches have been developed, the meeting has evolved to cover topics related to the use of novel cellular and antibody-based approaches for treating advanced solid tumors.

More than 20 world-renowned experts in the field of cellular and antibody-based tumor immuno-biology and autologous/allogeneic transplantation presented their latest data and discussed novel methods of potentiating immunity against cancer. The meeting was divided into multiple sessions addressing novel monoclonal antibody, immunotoxin, radio-immunoconjugates, and vaccine therapies for cancer as well as novel methods to augment NK-cell and T-cell-based antitumor immunity. The meeting also included sessions that updated the results of autologous and allogeneic transplants for solid tumors, as well as methods to enhance graft-vs-tumor effects utilizing tumor antigen-specific T-cells, alloreactive NK cells, and post-transplant tumor vaccine approaches.

This special issue of the Journal of Cancer includes a summary of each speaker\'s presentation from the ATST meeting.
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We hope that you enjoy this special issue of the Journal of Cancer.
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